Calidi Biotherapeutics Narrows Q1 Net Loss to $4.4M, Raises Cash to $6.6M and Secures AI Partnership
CLDI•Calidi Biotherapeutics narrowed its Q1 2026 net loss to $4.4M from $5.0M year-earlier, cut G&A expenses by $1.0M to $1.6M, and increased cash reserves to $6.6M. The company disclosed new CLD-401 and CLD-501 activation data at cancer research conferences and forged a TransferAI collaboration to streamline its CLD-401 IND filing.
1. Q1 2026 Financial Performance
Calidi reported a net loss attributable to common stockholders of $4.4 million, or $0.43 per share, for the quarter ended March 31, 2026, compared to a $5.0 million loss a year earlier. R&D expenses were $2.6 million versus $2.4 million, G&A expenses fell by $1.0 million to $1.6 million, and cash plus restricted cash rose to $6.6 million as of quarter end.
2. Clinical and Platform Developments
During the first quarter, Calidi presented data showing CLD-401 induced robust recruitment and activation of T, NK, NK-T and γδ T-cells in tumor models, and unveiled its first in situ T-cell engager, CLD-501, targeting TROP-2. Additional presentations highlighted IL-15-SA expression expanding the therapeutic window and a RedTail virus engineered to evade immune clearance and deliver high gene therapy payloads to tumors.
3. TransferAI Collaboration and IND Timeline
In April 2026, Calidi partnered with TransferAI to leverage its SofieTM AI platform for orchestrating regulatory workflows, aiming to complete the CLD-401 IND submission by year end. This strategic alliance is designed to enhance efficiency in document preparation, review and regulatory interactions, supporting the company’s goal of advancing its lead candidate into clinical trials.
